Elevated expression of LSD1 (Lysine-specific demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breast

Table 1 Clinicopathological and immunohistochemical parameters in relation to LSD1 immunoreactivity in invasive ductal breast carcinoma

Variable	LSD1 immunoreactivity
	n analysable	low^b	abundant^b	p^c
*Clinicopathological data:*
Tumour stage^a
Tumour stage^a	22	5	17	0.370
pT2	5	2	3
pT3	1	0	1
pT4	1	1	0
unknown	3
Lymph node status^a
pN0	16	1	15	0.010
pN1-3	9	5	4
unknown	7
Histological grade
G1	2	0	2	0.010
G2	16	1	15
G3	14	7	7
Histological type
ductal	32
*Immunohistochemistry (IHC):*
Oestrogen receptor status
negative (IRS 0–2)	10	6	4	0.004
positive (IRS 3–12)	22	2	20
Progesterone receptor status
negative (IRS 0–2)	14	6	8	0.090
positive (IRS 3–12)	18	2	16
HER2 status
weak (0-2+)	26	7	19	1.0
strong (3+)	6	1	5

^aAccording to UICC: TNM Classification of Malignant Tumours (7th edition). Sobin LH, Gospodarowicz MK, Wittekind CH (eds) Wiley-Blackwell, Oxford 2009.
^bLSD1 immunoreactivity: low = IRS 0–9, abundant = IRS 10–12.
^cFisher’s exact test (two-sided), bold face representing significant data (P <0.05).

ISSN: 1472-6890